202 related articles for article (PubMed ID: 19816574)
1. Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety.
Kellinghaus C
Ther Clin Risk Manag; 2009; 5():757-66. PubMed ID: 19816574
[TBL] [Abstract][Full Text] [Related]
2. Lacosamide: a review of preclinical properties.
Beyreuther BK; Freitag J; Heers C; Krebsfänger N; Scharfenecker U; Stöhr T
CNS Drug Rev; 2007; 13(1):21-42. PubMed ID: 17461888
[TBL] [Abstract][Full Text] [Related]
3. Lacosamide for the prevention of partial onset seizures in epileptic adults.
Kelemen A; Halász P
Neuropsychiatr Dis Treat; 2010 Sep; 6():465-71. PubMed ID: 20856610
[TBL] [Abstract][Full Text] [Related]
4. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures.
Beydoun A; D'Souza J; Hebert D; Doty P
Expert Rev Neurother; 2009 Jan; 9(1):33-42. PubMed ID: 19102666
[TBL] [Abstract][Full Text] [Related]
5. Lacosamide, a newer antiepileptic.
Patyar S; Medhi B
Neurosciences (Riyadh); 2010 Jan; 15(1):3-6. PubMed ID: 20677583
[TBL] [Abstract][Full Text] [Related]
6. Lacosamide: an adjunctive agent for partial-onset seizures and potential therapy for neuropathic pain.
Harris JA; Murphy JA
Ann Pharmacother; 2009 Nov; 43(11):1809-17. PubMed ID: 19843834
[TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapy of epilepsy: newly approved and developmental agents.
Stephen LJ; Brodie MJ
CNS Drugs; 2011 Feb; 25(2):89-107. PubMed ID: 21254787
[TBL] [Abstract][Full Text] [Related]
8. In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation.
Wang Y; Brittain JM; Jarecki BW; Park KD; Wilson SM; Wang B; Hale R; Meroueh SO; Cummins TR; Khanna R
J Biol Chem; 2010 Aug; 285(33):25296-307. PubMed ID: 20538611
[TBL] [Abstract][Full Text] [Related]
9. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
[TBL] [Abstract][Full Text] [Related]
10. Novel medications for epilepsy.
Fattore C; Perucca E
Drugs; 2011 Nov; 71(16):2151-78. PubMed ID: 22035515
[TBL] [Abstract][Full Text] [Related]
11. Lacosamide: a review of its use as adjunctive therapy in the management of partial-onset seizures.
Hoy SM
CNS Drugs; 2013 Dec; 27(12):1125-42. PubMed ID: 24203890
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of lacosamide as monotherapy and adjunctive therapy in focal epilepsy and its use in status epilepticus: clinical trial evidence and experience.
Bauer S; Willems LM; Paule E; Petschow C; Zöllner JP; Rosenow F; Strzelczyk A
Ther Adv Neurol Disord; 2017 Feb; 10(2):103-126. PubMed ID: 28382109
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study.
Del Bianco C; Placidi F; Liguori C; Mari L; Ulivi M; Ornello R; Pisani A; Mercuri NB; Izzi F
Epilepsy Behav; 2019 May; 94():178-182. PubMed ID: 30959275
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic drug evaluation of lacosamide for the treatment of partial-onset seizures.
de Biase S; Valente M; Gigli GL; Merlino G
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):997-1005. PubMed ID: 28750560
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive lacosamide in clinical practice: sodium blockade with a difference?
Stephen LJ; Kelly K; Parker P; Brodie MJ
Epilepsy Behav; 2011 Nov; 22(3):499-504. PubMed ID: 21890421
[TBL] [Abstract][Full Text] [Related]
16. Lacosamide: in partial-onset seizures.
Cross SA; Curran MP
Drugs; 2009; 69(4):449-59. PubMed ID: 19323588
[TBL] [Abstract][Full Text] [Related]
17. A prospective, multicenter, noninterventional study in Taiwan to evaluate the safety and tolerability of lacosamide as adjunctive therapy for epilepsy in clinical practice.
Wu T; Chuang YC; Huang HC; Lim SN; Hsieh PF; Lee WT; Cheng MY; Tsai MH; Jou SB; Chang CW; Hsieh HY; Du X; Hellot S; McClung C; Hung C
Epilepsy Behav; 2020 Dec; 113():107464. PubMed ID: 33152580
[TBL] [Abstract][Full Text] [Related]
18. Advances in epilepsy treatment: lacosamide pharmacokinetic profile.
Cawello W; Stockis A; Andreas JO; Dimova S
Ann N Y Acad Sci; 2014 Nov; 1329():18-32. PubMed ID: 25167889
[TBL] [Abstract][Full Text] [Related]
19. Activity of the anticonvulsant lacosamide in experimental and human epilepsy via selective effects on slow Na
Holtkamp D; Opitz T; Niespodziany I; Wolff C; Beck H
Epilepsia; 2017 Jan; 58(1):27-41. PubMed ID: 27864845
[TBL] [Abstract][Full Text] [Related]
20. Long-term exposure and safety of lacosamide monotherapy for the treatment of partial-onset (focal) seizures: Results from a multicenter, open-label trial.
Vossler DG; Wechsler RT; Williams P; Byrnes W; Therriault S;
Epilepsia; 2016 Oct; 57(10):1625-1633. PubMed ID: 27528101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
